Skip to content
DataLookout
Menu

NCT07939399

A Study of V951A in Healthy Participants (V951A-001)

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Percentage of Participants With Solicited Injection-Site Adverse Events (AE)
Timeframe: Up to 7 days after each vaccination
Percentage of Participants with Solicited Systemic AE
Timeframe: Up to 7 days after each vaccination
Percentage of Participants with Immediate Post-Vaccination AEs
Timeframe: Up to 30 minutes after each immunization
Percentage of Participants with Unsolicited AEs
Timeframe: Up to 28 days after each immunization
Percentage of Participants with Serious Adverse Events (SAEs)
Timeframe: Up to approximately 18 months
Percentage of Participants with Medically Attended AEs (MAAEs)
Timeframe: Up to approximately 18 months
Percentage of Participants with Adverse Events of Special Interest (AESIs)
Timeframe: Up to approximately 18 months

Secondary (2)

Geometric Mean Concentration (GMC) of V951A-Specific Antibodies
Percentage of Participants Achieving Seroconversion to V951A

Arms and interventions

V951A Group AExperimental

Healthy younger adult participants (typically aged 18 to 49) who will receive active injections of the investigational vaccine V951A. This group is evaluated to determine the vaccine's safety, tolerability, and early immune response in a younger population.

V951A Group BExperimental

Healthy older adult participants (typically aged 50 and older) who will receive active injections of the investigational vaccine V951A. This group is evaluated to determine the vaccine's safety, tolerability, and early immune response in an older population.

PlaceboPlacebo comparator

Healthy adult participants who will receive placebo injections containing no active vaccine. This group acts as a comparator to help researchers safely evaluate the effects of the active investigational vaccine.

Biologicals: V951A

Other: Placebo